Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.35 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.35 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562979 | 0.76 | PLK1 (0.44) | TLR7LMNAALDH1A1GAAMAPT | |
| SCHEMBL563625 | 0.75 | CCNC (0.44) | LMNAALDH1A1GAAMAPTMEN1 | |
| SCHEMBL562804 | 0.74 | ALDH1A1 (0.41) | TLR7ALDH1A1CNR2KCNH2 | |
| SCHEMBL563066 | 0.72 | CRHBP (0.44) | ALDH1A1GAAMAPTHTT | |
| SCHEMBL562914 | 0.68 | CDK5 (0.48) | LMNAALDH1A1GAAMAPT | |
| SCHEMBL11238635 | 0.66 | KCNH2 (0.38) | ALDH1A1MAPTKCNH2 | |
| SCHEMBL8600211 | 0.65 | ALDH1A1 (0.55) | LMNAALDH1A1GAAMAPTMEN1 | |
| SCHEMBL11798967 | 0.64 | ALDH1A1 (0.44) | TLR7LMNAALDH1A1MAPTHTT | |
| SCHEMBL562959 | 0.64 | CNR1 (0.32) | TLR7LMNAALDH1A1MAPTMEN1 | |
| SCHEMBL17315589 | 0.63 | TLR8 (0.43) | TLR7CSNK1EKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035209-A1 | Hydroxy Substituted 1H-Imidazopyridines and Methods | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20100152230-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | PFIZER INC. | 2010-06-17 | — | — | US | disclosed |
| EP-1924581-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | Pfizer, Inc. (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007028129-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | PFIZER INC. (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152230-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | IL4, IL2, IL4I1 | CYP19A1 3709/4885TLR7 210/4885DCTPP1 2571/4885 |
| US-20120035209-A1 | Hydroxy Substituted 1H-Imidazopyridines and Methods | IL2, IL4, IL4I1 | CYP19A1 3607/4885TLR7 231/4885DCTPP1 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.